• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.环氯茚醇(Wy 23409)在人类志愿者体内的药代动力学。
Br J Clin Pharmacol. 1977 Feb;4(1):61-5. doi: 10.1111/j.1365-2125.1977.tb00668.x.
2
Studies on the metabolism of the new anti-hypertensive agent, indoramin, in man.新型抗高血压药物吲哚拉明在人体中的代谢研究。
Eur J Clin Pharmacol. 1983;24(5):629-34. doi: 10.1007/BF00542212.
3
Studies on the metabolism of meptazinol, a new analgesic drug.新型镇痛药美普他酚的代谢研究。
Br J Clin Pharmacol. 1976 Jun;3(3):497-502. doi: 10.1111/j.1365-2125.1976.tb00627.x.
4
The pharmacokinetics of tetroxoprim in the dog.四氧普明在犬体内的药代动力学。
Eur J Drug Metab Pharmacokinet. 1982;7(3):197-202. doi: 10.1007/BF03189566.
5
Pharmacokinetics, metabolism and elimination of itanoxone in humans.伊他诺酮在人体内的药代动力学、代谢及消除
Eur J Drug Metab Pharmacokinet. 1983 Jul-Sep;8(3):287-96. doi: 10.1007/BF03188759.
6
[Pharmacokinetics and metabolite pattern of clenbuterol in the rat].[克伦特罗在大鼠体内的药代动力学及代谢物模式]
Arzneimittelforschung. 1976;26(7a):1435-41.
7
Disposition and metabolism of the new hypocholesterolemic compound S-8921 in rats and dogs.新型降胆固醇化合物S-8921在大鼠和犬体内的处置与代谢
Arzneimittelforschung. 1998 Oct;48(10):995-1006.
8
Pharmacokinetics and metabolism of premazepam, a new potential anxiolytic, in humans.新型潜在抗焦虑药普瑞马西泮在人体内的药代动力学及代谢情况
Int J Clin Pharmacol Ther Toxicol. 1984 May;22(5):273-7.
9
The biotransformation of ciclazindol in man.环氯茚在人体中的生物转化。
Br J Clin Pharmacol. 1979 Jan;7(1):120-3. doi: 10.1111/j.1365-2125.1979.tb00909.x.
10
Pharmacokinetics of intravenous pan-class I phosphatidylinositol 3-kinase (PI3K) inhibitor [C]copanlisib (BAY 80-6946) in a mass balance study in healthy male volunteers.静脉注射泛I类磷脂酰肌醇3-激酶(PI3K)抑制剂[C]库潘尼西(BAY 80-6946)在健康男性志愿者中的质量平衡研究的药代动力学
Cancer Chemother Pharmacol. 2017 Sep;80(3):535-544. doi: 10.1007/s00280-017-3383-9. Epub 2017 Jul 11.

引用本文的文献

1
Ciclazindol: an oral agent with weight reducing properties and hypoglycaemic activity.
Eur J Clin Pharmacol. 1983;25(1):41-5. doi: 10.1007/BF00544012.
2
Comparison of the effects of chronic administration of ciclazindol and desipramine on pupillary responses to tyramine, methoxamine and pilocarpine in healthy volunteers.健康志愿者长期服用环苯扎朵和地昔帕明对瞳孔对酪胺、甲氧明和毛果芸香碱反应的影响比较。
Br J Clin Pharmacol. 1985 May;19(5):639-47. doi: 10.1111/j.1365-2125.1985.tb02691.x.
3
Computer assisted shared care in hypertension.高血压的计算机辅助共享照护
Br Med J (Clin Res Ed). 1985 Jun 29;290(6486):1960-2. doi: 10.1136/bmj.290.6486.1960.
4
The biotransformation of ciclazindol in man.环氯茚在人体中的生物转化。
Br J Clin Pharmacol. 1979 Jan;7(1):120-3. doi: 10.1111/j.1365-2125.1979.tb00909.x.

本文引用的文献

1
Drug urinary excretion data--some aspects concerning the interpretation.药物尿液排泄数据——关于解读的一些方面。
Br J Pharmacol Chemother. 1967 Feb;29(2):181-93. doi: 10.1111/j.1476-5381.1967.tb01951.x.
2
Clinical implications of enzyme induction.酶诱导的临床意义。
Ann N Y Acad Sci. 1971 Jul 6;179:421-31. doi: 10.1111/j.1749-6632.1971.tb46919.x.
3
Folate deficiency after anticonvulsant drugs: an effect of hepatic enzyme induction?抗惊厥药物治疗后的叶酸缺乏:是肝酶诱导的作用吗?
Br Med J. 1972 Jan 29;1(5795):297-9. doi: 10.1136/bmj.1.5795.297.
4
The action of indoramin and other compounds on the uptake of neurotransmitters into rat cortical slices.吲哚拉明及其他化合物对神经递质摄取进入大鼠皮层切片的作用。
Br J Pharmacol. 1974 Jul;51(3):467-9. doi: 10.1111/j.1476-5381.1974.tb10687.x.
5
Pharmacokinetic studies on WY 23409 HCl.盐酸WY 23409的药代动力学研究。
Br J Clin Pharmacol. 1975 Oct;2(5):473-4. doi: 10.1111/j.1365-2125.1975.tb00561.x.

环氯茚醇(Wy 23409)在人类志愿者体内的药代动力学。

The pharmacokinetics of ciclazindol (Wy 23409) in human volunteers.

作者信息

Swaisland A J, Franklin R A, Southgate P J, Coleman A J

出版信息

Br J Clin Pharmacol. 1977 Feb;4(1):61-5. doi: 10.1111/j.1365-2125.1977.tb00668.x.

DOI:10.1111/j.1365-2125.1977.tb00668.x
PMID:843425
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1428987/
Abstract
  1. The pharmacokinetics and metabolism of ciclazindol, a potential anti-depressant drug, have been studied after oral administration of the compound to male and female volunteers. 2. The mean +/- S.E. mean maximum plasma concentration of the unchanged drug was 422 +/- 31 ng/ml. This level was seen between 2 and 4 h after dosing. 3. Elimination of the ciclazindol from plasma was apparently monexponential with a half-life of approximately 32 h. A large proportion of the drug-related substances in the plasma was unchanged drug. 4. Excretion of radioactivity took place predominantly via the renal route, less than 15% of the dose being recovered in the faeces. The urinary elimination process was apparently monoexponential with a half-life of 28 h. 5. Daily dosing with ciclazindol for 3 weeks did not appear to induce the enzymes of its own metabolism.
摘要
  1. 已对一种潜在的抗抑郁药物环氯茚朵在男性和女性志愿者口服该化合物后的药代动力学和代谢情况进行了研究。2. 未变化药物的平均最大血浆浓度为422±31纳克/毫升(均值±标准误)。该水平在给药后2至4小时出现。3. 环氯茚朵从血浆中的消除明显呈单指数形式,半衰期约为32小时。血浆中大部分与药物相关的物质是未变化的药物。4. 放射性物质的排泄主要通过肾脏途径进行,粪便中回收的剂量不到15%。尿液消除过程明显呈单指数形式,半衰期为28小时。5. 连续3周每日服用环氯茚朵似乎并未诱导其自身代谢的酶。